Exagen News

Buy Rating Affirmed for Exagen on Strong Financials and Strategic Growth Initiatives

TipRanksMar 20 05:56 ET

Exagen's Strong Q4 Performance and Positive Outlook Justify Buy Rating

TipRanksMar 18 19:05 ET

Exagen (XGN) Receives a Buy From BTIG

TipRanksJan 2 09:55 ET

Exagen (XGN) Gets a Buy From BTIG

TipRanksDec 31, 2023 05:28 ET

Exagen (XGN) Gets a Buy From Cantor Fitzgerald

TipRanksNov 14, 2023 07:58 ET

Analysts Offer Insights on Healthcare Companies: Exagen (XGN) and Milestone Pharmaceuticals (MIST)

TipRanksNov 13, 2023 21:30 ET

Cantor Fitzgerald Reiterates Overweight on Exagen, Maintains $6 Price Target

BenzingaSep 26, 2023 12:02 ET

Exagen Analyst Ratings

BenzingaSep 26, 2023 12:01 ET

Cantor Fitzgerald Reiterates Overweight on Exagen, Maintains $6 Price Target

BenzingaAug 22, 2023 11:55 ET

Exagen Analyst Ratings

BenzingaAug 22, 2023 11:54 ET

Cantor Fitzgerald Reaffirms Their Buy Rating on Exagen (XGN)

TipRanksMay 16, 2023 12:25 ET

Cantor Fitzgerald Reiterates Overweight on Exagen, Maintains $6 Price Target

BenzingaMay 16, 2023 08:39 ET

Analysts Offer Insights on Healthcare Companies: Outlook Therapeutics (OTLK) and Exagen (XGN)

TipRanksMay 16, 2023 07:10 ET

BTIG Adjusts Price Target on Exagen to $5 From $6, Maintains Buy Rating

MT NewswiresMar 22, 2023 08:49 ET

BTIG Maintains Buy on Exagen, Lowers Price Target to $5

BenzingaMar 22, 2023 08:17 ET

BTIG Keeps Their Buy Rating on Exagen (XGN)

TipRanksMar 21, 2023 21:31 ET

BTIG Adjusts Exagen's Price Target to $7 From $10, Keeps Buy Rating

MT NewswiresNov 17, 2022 08:15 ET

Exagen Analyst Ratings

Benzinga Analyst RatingsNov 17, 2022 07:02 ET

BTIG Maintains Buy on Exagen, Lowers Price Target to $7

Benzinga Real-time NewsNov 17, 2022 07:01 ET

Canaccord Genuity Cuts Price Target on Exagen to $7 From $8, Affirms Buy Rating

MT NewswiresNov 15, 2022 09:01 ET